I agree. You are correct when you analyse what we have.I don't...

I agree. You are correct when you analyse what we have.

I don't think there is any chance of a really big number in a takeover, that scenario is in a perfect world with a perfect buyer and everything going to plan but I do hold some optimism the potential of 2591 will mean whoever puts a bid in will pay a bit more than expected. So, on balance, it would equal a Reata number, maybe slightly lower, maybe, slightly higher.

If a Reata number is 85AUD, who would not take between $60 and $100 before a phase 3 trial placebo-controlled trial? I expect a lower-end number to test Neuren's self-belief before the real negotiating starts.

The risk-reward for Neuren leads me to believe this zone of offer would be acceptable to them. If 2591 is that good, someone will offer a figure between these numbers after the FDA meeting and disclosure of the new indications.

I think this scenario would leave both seller and buyer content.

Gone by Xmas.

Just my thoughts.